Clal Biotech: Has Pi-Cardia Moved From Clearance To Market Proof
FDA clearance, first commercial procedures in the U.S., and fresh financing have pushed Pi-Cardia beyond a pure regulatory option. But in Clal Biotech’s books it is still carried at only NIS 2.4 million, so the filing itself frames this as a funded launch, not full market proof yet.
What This Follow-Up Is Isolating
The main article already established that Clal Biotech’s private portfolio remains secondary to MediWound, and that even positive private-asset headlines do not automatically turn into accessible value at the parent. This follow-up isolates Pi-Cardia because the gap between the headline and the carrying line is especially sharp here: on one side there is FDA clearance, first commercial procedures in the U.S., and new financing. On the other side CBI itself shows only about a 4% economic exposure in section 2.16.1, while note 8(e) shows that the fair value recorded for the company and Anatomy holdings in Pi-Cardia stood at only about NIS 2.4 million at year-end 2025 after a roughly NIS 2.5 million decline.
The short answer is that Pi-Cardia has moved from regulatory proof into market testing, but not yet into full market proof. What has already been proven is that the product is approved, that the company reached initial commercial use in the U.S., and that it could still raise capital after clearance. What the filing does not yet prove is repeat commercial adoption, a disclosed sales run-rate, or a point where commercialization begins to replace dependence on outside funding.
What Has Been Proven, And What Has Not
| Milestone | What was disclosed | What it does prove | What it still does not prove |
|---|---|---|---|
| October 2024 | ShortCut received FDA market clearance in the U.S. | The product cleared the regulatory bottleneck | It does not yet prove broad commercial penetration |
| March 2025 | The first commercial procedures with ShortCut were performed in the U.S. | The story moved from theoretical approval to initial commercial use | It does not yet prove procedure volume, adoption rate, or revenue scale |
| March 2025 | Pi-Cardia is focusing its launch and marketing efforts on ShortCut in the U.S. and is not advancing patient recruitment for Leaflex | Management is narrowing execution around the lead commercial asset | It still does not prove a wider commercial platform |
| May 2025 and February 2026 | The company kept raising capital under its convertible-note framework | The company still has access to funding after clearance | It still does not prove that commercialization is funding itself |
The important point is the sequence. Many medical-device companies get stuck between regulatory clearance and real market use. Pi-Cardia did not get stuck there. After market clearance in October 2024, the filing already reported first commercial procedures in the U.S. in March 2025, and by that point the company had also narrowed its operating focus around ShortCut rather than continuing to push Leaflex patient recruitment in parallel.
That is a positive signal, but it is also a signal that the story has become narrower. Instead of two parallel engines, the filing shows one approved product entering launch mode, with both marketing and financing now concentrated around it. In other words, Pi-Cardia is no longer being judged mainly on whether it can get approved. It is being judged on whether ShortCut can move from an approved product to one that actually gains traction in the market.
Why Clal Biotech Still Carries It As A Residual Value
The critical section in this follow-up is note 8(e). That note shows that the fair value recorded for the company and Anatomy holdings in Pi-Cardia stood at year-end 2025 at about $0.7 million, or about NIS 2.4 million. Before the revaluation, the carrying amount stood at about $1.3 million, or about NIS 4.8 million. So in the same reporting year that already included FDA clearance and first commercial procedures, the holding was not marked up. It was marked down, by roughly NIS 2.5 million.
| Point | Figure | Why it matters |
|---|---|---|
| Clal Biotech’s rights in Pi-Cardia capital | about 4% | Even commercial success would have to become meaningful before it translates into a large value at CBI level |
| Carrying amount before the valuation update | about $1.3 million, NIS 4.8 million | The accounting starting point |
| Fair value at 31 December 2025 | about $0.7 million, NIS 2.4 million | The value recorded in the books for the holding |
| Fair-value change | decline of about NIS 2.5 million | The filing is still treating execution risk as material |
| Valuation method | Venture Capital | The holding is framed through a future-exit approach, not through already-proven commercial scale |
| Main assumptions | sales multiple of 4.4, discount rate of 42.5%, volatility of 56% | A high discount rate and high volatility mean the risk is still considered heavy |
That is the core of the analysis. If Pi-Cardia were already being treated as an asset with clear market proof, one would expect at least stability in carrying value or a different framing of the holding. Instead, the position is still valued through a Venture Capital approach, which means a future exit value based on forecast sales and a sales multiple, with a 42.5% discount rate laid on top. That is not the framing of a business that has already proven a repeat commercial ramp. It is the framing of a commercial option that still carries substantial execution risk.
This is also where the translation problem into CBI matters. Even if Pi-Cardia is genuinely moving forward at the company level, Clal Biotech only sits on about 4% of the capital. So the path from a positive commercialization headline to a material accounting change at the parent is not short in the first place. That is another reason the headline can look bigger than the book line.
The New Financing Bought Time, But It Also Shows Where The Company Still Stands
Note 8(e) together with note 19(b) gives a fairly clean financing sequence. In December 2023, Pi-Cardia raised about $15 million through convertible notes. That was later expanded by about $8.5 million. In May 2025, another roughly $15 million was added, taking the same funding framework to about $38.5 million by year-end 2025. After the balance-sheet date, in February 2026, another roughly $4 million extension was added. So under the same financing framework, Pi-Cardia had reached about $42.5 million.
That financing has two sides. On the positive side, it means the company did not stall immediately after clearance. It was able to keep attracting capital after moving into the commercial stage, and that matters because it buys time to build the U.S. launch, pursue business development, and explore strategic transactions. On the less comfortable side, the filing shows that this stage is still being supported by financing rather than by disclosed commercial metrics that already stand on their own.
The financing terms reinforce that point. By year-end 2025, the notes matured on 1 January 2028, carried 10% annual interest, converted into Pi-Cardia shares under predefined conditions including a future financing round or an M&A event, and also gave investors warrants equal to the amount they funded. This is financing that enables progress, but it is still bridge-stage financing. It does not look like a point where the company has already crossed into self-funding commercialization.
This is exactly where the filing draws the line between clearance and market proof. Market clearance means the product can enter the market. First commercial procedures mean the door is open. Fresh financing means investors are still willing to fund the attempt to walk through that door. But full market proof needs something else: repeatability, adoption visibility, and eventually an economic datapoint that begins to displace the need for external funding.
Bottom Line
Has Pi-Cardia moved from clearance to market proof? Not fully yet. It has clearly moved forward. The filing shows that the company is no longer only a regulatory story: there is FDA clearance, there are first commercial procedures, there is a tighter ShortCut-centered execution focus, and there are investors still willing to fund the move after approval. That is much more than a pre-clearance option.
But in the same breath, the filing still refuses to treat it as full market proof. The recorded value of the holding remains small, around NIS 2.4 million, the valuation framework remains a Venture Capital model with a very high discount rate, and the hard datapoints disclosed around the company are still mostly approval, first procedures, and funding rather than a commercial run-rate.
So the more accurate label is that Pi-Cardia has moved from clearance into a funded market test. That is already more than a regulatory promise, but it is still less than an asset that has proven it can penetrate the market at a pace strong enough to force a rewrite of its value inside Clal Biotech. For the line in the accounts to start looking different, the next filings will need to show not just more financing and more launch headlines, but commercial repetition that starts to line up with the carrying value as well.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.